Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus TAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus TAVIST.
BROMPHENIRAMINE MALEATE vs TAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Antihistamine; selective inverse agonist at histamine H1 receptors, blocking histamine-mediated allergic and inflammatory responses.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged in renal/hepatic impairment.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Renal excretion of metabolites (approx. 60%) and unchanged drug (<5%); biliary/fecal elimination accounts for about 40%.
Category C
Category C
Antihistamine
Antihistamine